COV.AU Cleo Diagnostics Ltd

Healthcare Health Care Equipment & Supplies Australian Securities Exchange
0.2950 AUD
Close of Oct 31, 2026
0.2700 0.9000
Market cap
AUD 42.0M
P/E
-
P/B
8.38x
ROE
-118.5%
Dividend yield
-
Fundamental score
0.5/5

Ratios use the latest price and the fiscal year ending Jun 2026.

Is COV.AU undervalued?

Graham number

The Graham number of Cleo Diagnostics Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Cleo Diagnostics Ltd fundamental analysis

3 of 21 checks passed

ROE 0/2

Low return on equity (-118.5%), below 10%.

ROA 0/1

Return on assets (-88.9%) is below the industry median (-35.3%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share history is shorter than 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 0/1

Last year's EPS growth (-39.1%) is below the industry median (24.9%).

Revenue Growth 0/2

Revenue did not grow over the past 3 years or is not reported.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 0/2

Debt to equity cannot be calculated: debt is not reported or equity is negative.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Cash Runway 1/2

Cash covers 1.3 years of the current cash burn.

PE vs Market 0/1

PE is negative or not available.

PE vs Industry 0/1

PE is negative or not available.

PBV 0/1

Price to book (8.4x) is above the industry median (4.0x).

Graham Number 0/1

Graham number needs positive earnings and book value.

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Cleo Diagnostics Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Cleo Diagnostics Ltd

Cleo Diagnostics Ltd, a biotechnology company, engages in the development and patent of a blood test for the detection of ovarian cancer in Australia. The company offers CleoDX pre-surgical triage tests which measures a combination of five biomarkers in serum to provide an accurate determination of malignancy risk prior to surgical referral. It also focuses on developing and testing intellectual property, testing the IP, and securing patents. Cleo Diagnostics Ltd was incorpo…

Full company profile